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Screening for Chlamydia trachomatis was done for 280 endocervical swab samples by PCR specific for
endogenous plasmid. Age dependency was seen in symptomatic patients, with a high chlamydial prevalence
rate (28%) found in younger women. Genotyping by restriction fragment length polymorphism analysis of omp1
PCR-positive samples showed serovars D, E, and F to be the most prevalent.
Chlamydia trachomatis is a major cause of sexually transmit-
ted disease (16). Serovars D to K are chiefly responsible for
urogenital infections; of these serovars, E, F, and D account
for up to 60 to 70% of these infections (1, 5, 14, 20). Epide-
miological studies of C. trachomatis infections in sexual con-
tacts have been few to date, which hampers the study of chla-
mydial transmission, its route of spread in a population, its
virulence factors, and the associated risk factors of C. tracho-
matis infections (12, 19). Compared with immunotyping, the
genotyping methods, particularly omp1 are more sensitive and
precise in revealing C. trachomatis variants within serovars as
well as in potential recombinants among serovars (13, 15, 18).
The present study was undertaken to understand the occur-
rence of C. trachomatis serovars in the genital tracts of infected
women, which will help in devising an effective screening pro-
gram for routine diagnosis of chlamydial infections, under-
standing the immunopathogenesis, and developing an effective
chlamydial control program.
Reference C. trachomatis standard serovars were kindly pro-
vided by T. Ossewaarde (National Institute of Public Health
and Environment Protection, Bilthoven, The Netherlands).
Cervical swabs (n  280) were obtained from patients (17)
attending the gynecology outpatient clinic for various gyneco-
logical reasons (abnormal vaginal discharge and pelvic pain) at
Safdarjang Hospital, New Delhi, India. Chlamydial DNA was
extracted from the clinical specimens by the alkali lysis method
(2). The study protocol was approved by the committee re-
sponsible for the evaluation of work involving human subjects.
Prior consent was obtained in all cases.
The clinical samples were first screened by a PCR specific
for the human -globin gene. The primers used for the human
-globin PCR were P1 (sense, 5 ACA CAA CTG TGT TCA
CTA GC) and P2 (antisense, 5 GAA ACC CAA GAG TCT
TCT CT). Samples positive in the -globin PCR were used for
C. trachomatis detection by using a plasmid PCR performed as
described previously. The plasmid primers P3 (sense, 5GAA
CAA ATC GTA TCT CGG) and P4 (antisense, 5GAA ACC
AAC TCT ACG TCG) generated a fragment of 517 bp in the
C. trachomatis-positive samples. The omp1 gene was amplified
by primers selected from the published sequences of the omp1
gene of C. trachomatis (L2) (21). The PCR mixture contained
25 pmol of each of the forward and reverse primers, 200 M
concentrations of each of the deoxynucleoside triphosphates
(dATP, dTTP, dGTP, and dCTP), 10 PCR buffer (containing
10 mM Tris HCl [pH 8.3], 50 mM KCl, 2.5 mM MgCl2, 0.01%
gelatin), and 0.1 U of Taq DNA polymerase (Gibco-BRL).
PCR was performed in a thermocycler as follows: 5 min at
95°C; 40 cycles each consisting of denaturation at 94°C for 1
min, annealing at 60°C for 1 min, and extension at 72°C for 2
min; and a final elongation step of 10 min at 72°C. Restriction
endonuclease digestion was performed with the restriction en-
zymes AluI, CfoI, HinfI, DdeI, and EcoRI (Promega, Madison,
Wis.) on 5-l amounts of the amplified 871-bp PCR products
by following the manufacturer’s instructions.
All samples shown positive by the -globin PCR assay were
further screened by a plasmid PCR specific for the C. tracho-
matis endogenous plasmid. A clear age dependency was ob-
served, showing a high prevalence rate among younger women.
The overall prevalence rates of C. trachomatis in cervical swabs
as determined by plasmid PCR were 28.5% in group I (age, 18
to 25 years), 7.6% in group II (age, 25 to 35 years), and 3.2%
in group III (age, 35 to 45 years). C. trachomatis-positive swabs
detected by plasmid PCR were further examined by omp1 PCR
for genotyping by restriction fragment length polymorphism.
Purified PCR products were digested with AluI to differentiate
serovars of C. trachomatis (Fig. 1). Serovars D and E showed
fragments varying from 244 to 91 bp in size. Serovars B and D
had a closely related pattern, except for the presence (serovar
B) or absence (serovar D) of a 91-bp band in the digestion
profile with AluI. The standard serovar F showed fragment
sizes of 321 to 80 bp after digestion. Standard serovars L3 and
I, which are in the C complex, showed fragment of sizes 486 to
92 bp after digestion with AluI.
Serovars H, L3, and I were further distinguished by enzyme
digestion with EcoRI and DdeI. With EcoRI, serovar I gave
two bands, whereas with DdeI, it gave four bands varying be-
tween 323 to 80 bp in size. The clinical samples which were
identified as having banding patterns matching that of serovar
D after digestion with the AluI enzyme were further differen-
* Corresponding author. Mailing address: Institute of Pathology-
ICMR, Safdarjang Hospital Campus, Post Box No. 4909, New Delhi
110 029, India. Phone: 091-11-26198402. Fax: 091-011-6198401. E-
mail: amittal_iop@yahoo.com.
2700
tiated by digesting them with CfoI restriction enzyme. After
analysis with the CfoI restriction enzyme, clinical samples were
identified as serovar D, since they had an identical banding
pattern as that of the standard serovar D. The restriction
endonuclease sites for the various restriction enzymes are
listed in Table 1.
C. trachomatis serovar D (48%) was found to be the most
prevalent, followed by serovars E (34%), F (12%), and I (6%)
in urogenital samples.
The present study demonstrated that the prevalence of
symptomatic C. trachomatis infection is high in cervical swabs,
as determined by a sensitive PCR assay, and is age dependent.
These data are in agreement with earlier published reports
showing high C. trachomatis rates (6, 10). The clinical samples
could be discriminated by restriction endonuclease digestion
with AluI. However, for a few clinical samples, digestion with
HinfI, DdeI, CfoI, and EcoRI was done, which further aided in
discriminating among C. trachomatis serovars.
In our study, serovar D (48%) was found to be the most
prevalent serovar, followed by serovars E (34%), F (12%), and
I (6%) in the urogenital samples. A similar distribution of C.
trachomatis serovars has been reported earlier with tissue cul-
ture isolates (11). This pattern of serovar prevalence was found
to be in accordance with the distribution of C. trachomatis
serovars in other regions of the world (4, 7, 8, 9). We were not
able to find other serovars J, H, K, or G of C. trachomatis,
which have been reported by few workers (1, 3, 12). We did not
observe any restriction endonuclease pattern different from
the prototype or known variant strains in the 50 clinical sam-
ples examined. But this would have not been surprising, as
others have found only a limited number of variants by sero-
logic methods. In conclusion, C. trachomatis genotyping in
women younger than age 30 years revealed that serovars D and
E were more frequently found in symptomatic patients. The
procedure we have used for cervical swabs by PCR restriction
fragment length polymorphism analysis should enable basic
serovar identification and provide a springboard for studies of
variation.
This work was partly supported by the Department of Biotechnol-
ogy, New Delhi, India.
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